QuidelOrtho is an attractively valued diagnostics company with a forward P/E of 6.0x and a strong recent earnings track record, but high short interest of 24%, declining revenue of -10%, and a market cap below the $1 billion investable threshold create significant headwinds that must be resolved before the value opportunity can be realized.
Thesis pillars
- Below Investable Market Cap↑Improving
- Deep Value Forward Pe↑Improving
- Earnings Beat Streak Recovery↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026
QuidelOrtho Corporation (QDEL) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $13.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 26%; Below-average business quality; Below long-term trend.
QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine — serving customers in more than 140 countries through direct sales and distributors. Respiratory... Read more
Sell if holding. Engine safety override at $13.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 26%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 60. Score 5.4/10, moderate confidence.
Passes 5/10 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-28Recent Developments — QuidelOrtho Corporation
Latest news
- NEWS QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026 — fiscal.ai Oct 20, 2026
- NEWS QuidelOrtho Reports Q2 2026 Results: Full Earnings Call Transcript — benzinga Oct 13, 2026 neutral
- NEWS Nasdaq Gains Over 300 Points; US Employers Cut 23,000 Jobs In July — benzinga Aug 7, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Friday's Intraday Session — benzinga Aug 7, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga Aug 7, 2026 neutral
Generated 2026-10-28T11:53:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWProductrespiratory products15%10-K Item 1A: 'sales of our respiratory products accounted for approximately 15% of our total revenues for the year ended December 28, 2025'
- HIGHSuppliersingle and sole source suppliers10-K Item 1A: 'our reliance on a small number of contract manufacturers and a large number of single and sole source suppliers'
- MEDIUMCustomerkey distributors10-K Item 1A: 'we rely on certain key distributors for the sales of some of our products'
Material Events(8-K, last 90d)
- 2026-06-23Item 5.02MEDIUMBoard appointed Micah Young as CFO effective July 6, 2026, succeeding Joseph M. Busky, who previously announced plans to retire (disclosed February 13, 2026). Busky continues in his role through the effective date under a transition and retirement agreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -39.2%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.59: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 26%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 60. Prior stop was $12.64. Score 5.4/10, moderate confidence.
Analyst target $12.47 reached (−8.3% from $13.59); no take-profit level is published. Prior stop was $12.64. Stop-loss: $12.64.
Concentration risk — Supplier: single and sole source suppliers; Target reached (-8.3% upside); Quality below floor (2.8 < 4.0).
QuidelOrtho Corporation trades at a P/E of N/A (forward 9.5). TrendMatrix value score: 8.1/10. Verdict: Sell.
8 analysts cover QDEL with a consensus score of 2.4/5. Average price target: $15.
What does QuidelOrtho Corporation do?QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular...
QuidelOrtho develops and sells in-vitro diagnostic instruments and tests across four business units — Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine — serving customers in more than 140 countries through direct sales and distributors. Respiratory diagnostics products, including the QuickVue and Sofia platforms, accounted for approximately 15% of total revenue in fiscal 2025, while the company winds down its U.S. donor-screening portfolio, expected substantially complete by the first half of 2026.